BEUDAMED
    FDA PMA FDA Class 3 Approved 🇺🇸 United States

    Fluorescence In Situ Hybridization, Anaplastic Lymphoma Kinase, Gene Rearrangement

    PMA: P110012 · Supplement: S007 · Decision Dec 10, 2014
    View on FDA
    Classifications
    1
    FEI Numbers
    1
    Registration Numbers
    1

    Basic Information

    Device Name
    Fluorescence In Situ Hybridization, Anaplastic Lymphoma Kinase, Gene Rearrangement
    Trade Name
    VYSIS ALK BREAK APART FISH PROBE KIT
    PMA Number
    P110012
    Supplement Number
    S007
    Device Class
    FDA Class 3
    Product Code
    OWE
    Generic Name
    Fluorescence in situ hybridization, anaplastic lymphoma kinase, gene rearrangement
    Medical Specialty
    Unknown
    Advisory Committee
    Pathology
    Decision
    Approved
    Decision Code
    APPR
    Decision Date
    December 10, 2014
    Date Received
    August 14, 2014
    Supplement Type
    Real-Time Process
    Supplement Reason
    Labeling Change - Indications/instructions/shelf life/tradename
    Expedited Review
    N

    Advisory Committee Statement

    APPROVAL FOR MODIFICATIONS TO THE PROBECHK ALK POSITIVE AND NEGATIVE CONTROL SLIDE LABELING, AND EXPANSION OF THE ASSAY GUARD BAND PARAMETERS.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    OWE Fluorescence In Situ Hybridization, Anaplastic Lymphoma Kinase, Gene Rearrangement